Targeting ETV1 in Gastrointestinal Stromal Tumors: Tripping the Circuit Breaker in GIST?

Overview

Journal Cancer Discov

Specialty Oncology

Date 2015 Mar 10

PMID 25749973

Citations 4

Authors

Anette Duensing

Affiliations

Soon will be listed here.

Abstract

Activating mutations in the KIT or PDGFRA receptor tyrosine kinase genes are the key oncogenic drivers in the majority of gastrointestinal stromal tumors (GIST), but novel results now show that aberrant kinase signaling is potentiated by a positive feedback circuit that involves the ETS transcription factor ETV1. Targeting ETV1 can disrupt this circuit and represents a promising new therapeutic approach for the treatment of GISTs.

Citing Articles

ADRB2 Regulates the Proliferation and Metastasis of Gastrointestinal Stromal Tumor Cells by Enhancing the ETV1-c-KIT Signaling.

Chen S, Wu F, Zhang J, Zhu J, Zhou X, Zhi X J Oncol. 2023; 2023:6413796.

PMID: 36778918 PMC: 9918370. DOI: 10.1155/2023/6413796.

Function and regulation of the PEA3 subfamily of ETS transcription factors in cancer.

Qi T, Qu Q, Li G, Wang J, Zhu H, Yang Z Am J Cancer Res. 2020; 10(10):3083-3105.

PMID: 33163259 PMC: 7642666.

CeRNA Expression Profiling Identifies KIT-Related circRNA-miRNA-mRNA Networks in Gastrointestinal Stromal Tumour.

Jia N, Tong H, Zhang Y, Katayama H, Wang Y, Lu W Front Genet. 2019; 10:825.

PMID: 31552107 PMC: 6746987. DOI: 10.3389/fgene.2019.00825.

Promoter capture Hi-C-based identification of recurrent noncoding mutations in colorectal cancer.

Orlando G, Law P, Cornish A, Dobbins S, Chubb D, Broderick P Nat Genet. 2018; 50(10):1375-1380.

PMID: 30224643 PMC: 6380472. DOI: 10.1038/s41588-018-0211-z.